![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
London Asia | LSE:LDC | London | Ordinary Share | GB0008251513 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:7627L London Asia Capital PLC 3 May 2005 For immediate release: 3 May 2005 LONDON ASIA CONTINUES TO EXPAND NEW CORPORATE MANDATES SECURED London Asia Capital PLC ("London Asia" or "the Company"), the Greater China focused investment and merchant banking group, has been appointed corporate finance adviser to coal mining group Jiangsu Xuzhou Tianneng Group ("Tianneng") and Hubei Pharmaceutical Co. Ltd. ("Hubei Pharma"). Tianneng is a coal mine company currently 100% held by Xuzhou Local Government, Jiangsu Province, with exploitable coal deposits of around 50 million tons, detected coal deposits of some 130 million tons and forecasted coal deposits of more than 200 million tons. London Asia is working together with Golden Concord Holdings Limited ("GCHL"), a specialist investment holding company focusing on investment in companies and projects in clean energy, power generation and environment protection, to reform and restructure Tianneng. GCHL will acquire the coal deposit as well as the associated operating assets of Tianneng to form a foreign invested coal mine company. London Asia has been appointed as the exclusive corporate finance advisor to the project and will provide Corporate Finance and project finance advisory services. London Asia also intends to raise money for the project from international markets with a view to ultimately bringing the business to IPO or trade sale. Hubei Pharma is a new company set up as part of the restructuring of Hubei Zhongtian Airbeck Pharmaceutical ("Airbeck"), a long established Chinese pharmaceutical business, part owned by Hubei Province. London Asia has been appointed to restructure the business, including disposing of certain divisions in order to focus the business; to raise new capital from overseas investors; and acquire new technologies to help the business expand. Under the terms of the appointments, London Asia will receive both success based fees and preferential investment terms. Simon Littlewood, London Asia Chief Executive, commented: "We continue to build on our advisory activities in China, which generate revenue and investment opportunities for us. The diversity of the mandates we are currently winning underscores the appetite for professional corporate finance advice across China's central provinces. Tianneng is the third mandate we have recently won in the resource and energy fields and also means we are now active in the important Jiangsu province." For further information please visit www.londonasia.com or contact: Simon Littlewood, Chief Executive Jeremy Wright Jeremy Carey London Asia Capital Seymour Pierce Tavistock Communications Tel: 020 7248 7578 Tel: 020 7107 8000 Tel: 020 7920 3150 Notes to Editors About London Asia Capital plc London Asia is an AIM listed investment and merchant banking group focused on the SME market in Greater China. London Asia operates three principal businesses: * Investment of own funds in profitable businesses in Greater China, with exits via IPO or trade sale; * Investment Banking services, mainly corporate finance advisory (fund raisings, IPO's, M&A and restructurings); and * Fund management London Asia has offices and management teams, as well as strong local partners, across the Greater China region. These work in conjunction with our international network in London, New York, Hong Kong and Singapore. About Xuzhou, Jiangsu Province Xuzhou, a city under the jurisdiction of Jiangsu Province and located at the junction of the four provinces of Jiangsu, Shandong, Henan and Anhui, lies at the joint part of the Yangtze River Delta and the Pan-Bohai Sea Gulf. It is the central city of the Huaihai Economic Zone radiating to the surrounding 18 cities with a population of 120 million. Xuzhou is a booming industrial city with a population of over 9 million. Xuzhou is an important national industrial base for energy, engineering, machinery, foodstuff, electronics, chemicals and construction materials. Xuzhou has 140 large and medium key enterprises of state-class, 5 of which have been listed into China's 500 strongest enterprises. Xuzhou has made outstanding economic achievements in its effort to open to the outside world. By the end of 2000, the number of foreign invested companies had reached 1,300. This information is provided by RNS The company news service from the London Stock Exchange END MSCDKLFLEZBZBBX
1 Year London Asia Capital Chart |
1 Month London Asia Capital Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions